1A policy study on NDA/BLA expedited pathways in China, US and EUREN Xiao-xing, SHI Lu-wen961-9712Suggestions to Chinese manufacturers of pharmaceutical packing materials under the policy of associated evaluationQIAN Jing-yi, LIU Bo-yan, YU Zheng972-9773Patent application in pharmaceutical crystal field and the examination of its inventive stepLI Xue-ying, WANG Jing, ZHU Wei978-9824Data extrapolation strategy and general consideration for the products approved for pediatric use overseaGENG Ying, SUN Yan-zhe, LI Qiang, ZHANG Hao, ZHAO De-heng, YANG Zhi-min983-9865Analysis of FDA assessment consideration on cannabidiol indicated for refractory epilepsyGUAN Hong-feng, LIU Li-hua, DA Hong-yuan, ZHANG Yong-wen987-9926The determination of rituximab and its biosimilar in human serum by ELISALI Li, CHEN Jie, LI Kun, JIA Zhi-jun, ZOU Jia, CHEN Fang, DONG Li-hou, OU Lun, DONG Jing, SONG Hai-feng993-10007Advances in drug research for retinal diseasesQIAN Yi-min, LU Wen, WANG Ruo-nan, LI Hua1001-10068Progress in the application of PD-1/PD-L1 inhibitors in neoadjuvant chemotherapyQIU Xue-jia, ZHANG Yue, LIAN Yu-fei, LI Xiao-ming, CAO Ge-xi, DUAN Bao-jing1007-10119Recent advances in anticancer agent targeting Ras proteinsZHANG Yuan, XU Wen-qing1012-101710The effects of butylphthalide on patients with progressive infarction and the serum IL-6 and protein expression of S100BYANG Jing, LI Feng, SHI Chang-qing1018-102211Consensus on the extended dosing after clinical trials of registered anti-cancer drugs (2019 Version)China Anti-Cancer Association Chinese Oncology Clinical Trials Auditing Group1023-102612Consensus on the central laboratory usage in antitumor drug clinical trials(2019 Version)China Anti-Cancer Association Chinese Oncology Clinical Trials Auditing Group1027-103213Correlation between pharmacokinetics and in vitro dissolution of terazosin hydrochloride capsules in Beagle dogsCHEN Meng-ke, WU Yi-fan, CHEN Wei-dong1033-103914Effect of vancoglycosamine on vancomycin-induced phagocytosis in mouse macrophages RAW 264.7CHEN Zhi-hong, WEI Wei, CHEN Dai-jie, YIN Yu1040-104415Absorption characteristics of dioscin nano-structured lipid carriers in rat intestineHU Kun-xia, JIAO Ying, JU Hong-ye, HAN Li-zhu, WANG Bin, TANG Zhi-shu, SONG Xiao1045-105116Determination of six caffeoylquinic acids in Periploca forrestii and HPLC fingerprint studyMA Xue, HE Yan-ling, LIU Wen-jing, ZHENG Lin, LI Yue-ting, WANG Guang-cheng, LI Yong-jun1052-105817Pharmacoeconomic evaluation on the treatment of chronic hepatitis CWEI Xia, YANG Li1059-106818A comparative study on the degree of compliance between drug therapy and domestic guidelines for patients with pulmonary embolism based on a registry studyZHANG Jing, YAN Ying-ying, ZHAI Suo-di1069-107219A quick data mining and analysis of lopinavir/ritonavir (LPV/r) adverse events based on Eudravigilance Medicines Safety DatabaseTIAN Xiao-jiang, JIA Yun-tao, WANG Ke-jing, CHEN Lin1073-1080 